Growth Metrics

Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2010 - 2026)

Whitehawk Therapeutics (WHWK) reported Income from Continuing Operations of 22194000.0 for Q1 2026, down 130.4% year-over-year from 73016000.0 in Q1 2025, and down 125.57% on a QoQ basis from 86799000.0 in Q4 2025.

Whitehawk Therapeutics (WHWK) has 17 years of Income from Continuing Operations data on file, last reported at 22194000.0 in Q1 2026.

  • Quarterly Income from Continuing Operations fell 130.4% year-over-year to 22194000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5861000.0 (down 121.22% YoY) and the FY2025 annual result came in at 20596000.0, up 67.66% from the prior year.
  • Income from Continuing Operations fell to 22194000.0 in Q1 2026 per WHWK's latest filing, from 86799000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 86799000.0 in Q4 2025 and bottomed at 52770000.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 16269000.0 (2023), against an average of 7224117.65.
  • The widest annual swing landed in 2022, when Income from Continuing Operations plunged 1089.39%; it then jumped 575.01% in 2025.
  • Tracing WHWK's Income from Continuing Operations over 5 years: stood at 13913000.0 in 2022, then fell by 16.93% to 16269000.0 in 2023, then declined by 12.32% to 18273000.0 in 2024, then jumped by 575.01% to 86799000.0 in 2025, then tumbled by 125.57% to 22194000.0 in 2026.
  • Per Business Quant, the three latest WHWK Income from Continuing Operations figures stand at 22194000.0 (Q1 2026), 86799000.0 (Q4 2025), and 17696000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Whitehawk Therapeutics 312.26 Mn 189.22 Mn - -22.19 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -22.19 Mn
Dec 31, 2025 86.80 Mn
Sep 30, 2025 -17.70 Mn
Jun 30, 2025 -52.77 Mn
Mar 31, 2025 73.02 Mn
Dec 31, 2024 -18.27 Mn
Sep 30, 2024 -12.55 Mn
Jun 30, 2024 -14.58 Mn
Mar 31, 2024 -18.29 Mn
Dec 31, 2023 -16.27 Mn
Sep 30, 2023 -16.30 Mn
Jun 30, 2023 -17.97 Mn
Mar 31, 2023 -15.22 Mn
Dec 31, 2022 -13.91 Mn
Sep 30, 2022 -14.47 Mn
Jun 30, 2022 -18.27 Mn
Mar 31, 2022 -13.86 Mn
Dec 31, 2021 -15.99 Mn
Sep 30, 2021 -87.09 Mn
Jun 30, 2021 -1.54 Mn
Mar 31, 2021 -5.48 Mn
Dec 31, 2020 8.02 Mn
Sep 30, 2020 -2.89 Mn
Jun 30, 2020 9.28 Mn
Mar 31, 2020 -4.00 Mn
Dec 31, 2019 -4.49 Mn
Sep 30, 2019 -4.73 Mn
Jun 30, 2019 -5.69 Mn
Mar 31, 2019 -8.51 Mn
Dec 31, 2018 -8.52 Mn
Sep 30, 2018 11.53 Mn
Jun 30, 2018 -5.99 Mn
Mar 31, 2018 -7.43 Mn
Dec 31, 2017 -6.24 Mn
Sep 30, 2017 -4.70 Mn
Jun 30, 2017 -5.53 Mn
Mar 31, 2017 -5.03 Mn
Dec 31, 2016 -3.54 Mn
Sep 30, 2016 -4.91 Mn
Jun 30, 2016 -4.47 Mn
Mar 31, 2016 -4.21 Mn
Dec 31, 2015 -11,832.00
Sep 30, 2015 -6,521.00
Jun 30, 2015 -7,272.00
Mar 31, 2015 -5,815.00
Dec 31, 2014 -11,653.00
Sep 30, 2014 -6,428.00
Jun 30, 2014 -6,952.00
Mar 31, 2014 -5,766.00
Dec 31, 2013 -9,750.00
Sep 30, 2013 -6,139.00
Jun 30, 2013 -6,749.00
Mar 31, 2013 -6,063.00
Dec 31, 2012 -9,662.00
Sep 30, 2012 -6,038.00
Jun 30, 2012 -6,303.00
Mar 31, 2012 -5,362.00
Dec 31, 2011 -8,934.00
Sep 30, 2011 -6,337.00
Jun 30, 2011 -6,760.00
Mar 31, 2011 -5,154.00
Dec 31, 2010 -7,746.00
Sep 30, 2010 -4,767.00